Chad E. Beyer
Discovery Neuroscience
Wyeth Research
Princeton
NJ 08543-8000
USA
Name/email consistency: high
- Preclinical characterization of WAY-211612: a dual 5-HT uptake inhibitor and 5-HT (1A) receptor antagonist and potential novel antidepressant. Beyer, C.E., Lin, Q., Platt, B., Malberg, J., Hornby, G., Sullivan, K.M., Smith, D.L., Lock, T., Mitchell, P.J., Hatzenbuhler, N.T., Evrard, D.A., Harrison, B.L., Magolda, R., Pangalos, M.N., Schechter, L.E., Rosenzweig-Lipson, S., Andree, T.H. Br. J. Pharmacol. (2009)
- Do selective serotonin reuptake inhibitors acutely increase frontal cortex levels of serotonin? Beyer, C.E., Cremers, T.I. Eur. J. Pharmacol. (2008)
- Alpha 2A-adrenoceptors enhance the serotonergic effects of fluoxetine. Beyer, C.E., Lin, Q., Rosenzweig-Lipson, S., Schechter, L.E. Eur. J. Pharmacol. (2006)
- Regulators of G-protein signaling 4: modulation of 5-HT1A-mediated neurotransmitter release in vivo. Beyer, C.E., Ghavami, A., Lin, Q., Sung, A., Rhodes, K.J., Dawson, L.A., Schechter, L.E., Young, K.H. Brain Res. (2004)
- Comparison of the effects of antidepressants on norepinephrine and serotonin concentrations in the rat frontal cortex: an in-vivo microdialysis study. Beyer, C.E., Boikess, S., Luo, B., Dawson, L.A. J. Psychopharmacol. (Oxford) (2002)